Vertex Pharmaceuticals demonstrates resilience with robust CF franchise, new approvals, and diversification efforts. Read why ...

Below is a chart showing the trailing twelve month trading history for Vertex Pharmaceuticals, Inc., and highlighting in green where the $450.00 strike is located relative to that history ...

The company’s earnings surprise history is mixed ... On Feb. 11, Scotiabank raised Vertex Pharmaceuticals' price target to $450 from $433, citing strong Q4 results and higher sales expectations ...

With a market cap of $118.7 billion, Vertex Pharmaceuticals Incorporated (VRTX) is a global biotechnology leader specializing ...

The pharma industry is delivering game-changing therapies with favorable regulatory support. Amid this backdrop, investors ...

SFA Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel oral small-molecule biosynthetic compounds for the treatment of inflammatory and autoimmune diseases, today ...

As International Women's Day and Women's History Month shine a spotlight on the achievements of women around the world, Medical Solutions is proud to celebrate the exceptional women leading the ...

It's likely that 2024 as a whole will represent something of a lull in CRISPR's history. In its earnings report ... beta-thalassemia medicine it developed in collaboration with Vertex Pharmaceuticals.

For company updates and to learn more about Vertex's history of innovation ... and reference the “Vertex Pharmaceuticals Fourth Quarter 2024 Earnings Call.” The conference call will be ...

Sickle cell disease is a severe, inherited blood disorder that primarily affects people of African, Mediterranean, Middle Eastern, and Indian descent.

Initial data from the Heart-2 Phase 1b clinical trial of VERVE-102 targeting PCSK9 expected in the second quarter of 2025, with final dose ...